Moregate/Adult Bovine Serum - Defibrinated Raw (ABSD)/null/ABSD

The European Directorate for the Quality of Medicines (EDQM) has originated from the European Pharmacopoeia Secretariat which, with the addition of new responsibilities changed its name to the European Department for the Quality of Medicines (EDQM).? The EDQM sits alongside the European Medicines Agency (EMEA).

Amongst other activities, the EDQM is responsible for the European Pharmacopeia and the issuing of Certificates of Suitability (CEP).

Certificates of Suitability (CEP) are?recognised?by all signatory states of the European Pharmacopoeia Convention and by the European Union. Other countries have also chosen to recognise them.? In the case of Fetal Bovine Serum and other Bovine Serum a CEP can be used by the manufacturers of Fetal Bovine Serum and other Bovine Serum which is intended for use in the manufacture of pharmaceutical products to demonstrate compliance with the Bovine Serum monographs of the European Pharmacopoeia and the EDQM requirements for substances concerned by TSE risk.

The discovery of Bovine Spongiform Encephalopathy (BSE), which is one of a group of similar infections now referred to as Transmissible Spongiform Encephalopathies (TSEs), and it’s spread over many countries of the European Union as well as its discovery in Canada, the USA and Japan is well known. The European events provided the impetus for the Council of Europe Public Health Committee (CEPHC) to pass Resolution AP-CSP (99) 5 addressing the TSE concerns and creating a Certificate of Suitability (COS) pursuant to Directive 75/318/EEC.

The granting of a CoS to a manufacturer, for a particular product, certifies that the product in question has been assessed for the level of risk of transmission of TSEs, and that the risk level is considered low enough that the product is certified as suitable for use in the manufacture of medicinal products in the European Union.

The process of approval requires the manufacturer to submit a dossier that covers all relevant aspects of the collection of raw material and further processing that is performed to reach the product that is offered to end users. This dossier is detailed and covers the specific material that is collected, the collection method, process validation, testing, traceability, quality systems and an expert review.

Only after this dossier has been examined and approved by two rapporteurs and, if necessary, by a panel of experts appointed by the European Directorate for the Quality of Medicines (EDQM) is the manufacturer granted a COS. ??

Moregate Biotech has been granted a COS for:

?? ?- Fetal Bovine Serum – Australian Origin – CEP2000-187
?? ?- Fetal Bovine Serum – New Zealand Origin – CEP2000-188
?? ?- Adult Bovine Serum - New Zealand Origin – CEP2001-093
?? ?- Adult Bovine Serum (Defibrinated) - New Zealand Origin – CEP2000-174
?? ?- Bovine Plasma – New Zealand Origin – CEP2003-199
?? ?- Bovine Serum Albumin – manufactured in Australia from New Zealand origin Bovine Plasma – CEP2003-205
?? ?- Bovine Plasma – Australian Origin - CEP 2005-192
?? ?- Bovine Serum Albumin – manufactured in Australia from Australian origin Bovine Plasma - CEP 2005-191
Copies of the Certificates of Suitability are available upon request